AnaptysBio Inc "Previewing pot'l outcomes for the upcoming bench trial of..."

Research evidence excerpt

AnaptysBio Inc "Previewing pot'l outcomes for the upcoming bench trial of..."

at all. The recipient should carefully read this document in its

entirety and not draw inferences or conclusions from the rating alone. By receiving this document, the recipient acknowledges and agrees with the intended

purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports

to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain

categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky

and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a

copy of "The Characteristics and Risks of Standardized Options." You may read the document at https://www.theocc.com/publications/risks/riskchap1.jsp or ask

your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for

any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of

future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because

of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes